Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410979 | 0.85 | MET (0.48) | ABL1NPC1RAB9ASMN1; SMN2MET | |
| SCHEMBL2799688 | 0.85 | ABL1 (0.67) | ABL1NPC1RAB9ASMN1; SMN2MET | |
| SCHEMBL2783224 | 0.84 | ABL1 (0.57) | ABL1NPC1RAB9ASMN1; SMN2MET | |
| SCHEMBL613934 | 0.84 | ABL1 (0.69) | ABL1SMN1; SMN2METCYP3A4 | |
| SCHEMBL2868610 | 0.75 | MET (0.79) | METCYP3A4 | |
| SCHEMBL23900995 | 0.73 | ABL1 (0.66) | ABL1NPC1RAB9ASMN1; SMN2MET | |
| SCHEMBL543789 | 0.73 | ABL1 (0.69) | ABL1SMN1; SMN2METCYP3A4 | |
| SCHEMBL13188309 | 0.72 | ABL1 (0.48) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL544953 | 0.71 | ABL1 (0.55) | ABL1NPC1RAB9ASMN1; SMN2MET | |
| SCHEMBL23901243 | 0.71 | ABL1 (0.64) | ABL1NPC1RAB9ASMN1; SMN2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321777-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2016-04-26 | — | — | US | claimed |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2015-12-03 | — | — | US | claimed |
| US-9321777-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2015-12-03 | — | — | US | disclosed |
| US-9115134-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI (FR) | 2014-01-02 | — | — | US | disclosed |
| EP-2178881-B1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2178881-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | Sanofi-Aventis (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009056692-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | ABL1 8/4885NPC1 4725/4885RAB9A 1471/4885 |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | ABL1 8/4885NPC1 4725/4885RAB9A 1471/4885 |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | BMX, MET, TPMT | ABL1 20/4885NPC1 4613/4885RAB9A 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.